Guy Tolhurst from Intelligent Partnership interviews Louise Farley, Head of Business Development at Deepbridge. Farley explains why Life Science and tech innovation has been at the heart of the company’s alternative investment products, and how its application of patient capital enables Deepbridge to support companies from SEIS to EIS stage. She then goes onto discuss benefits of renewable energy in its IHT offering and the company’s expansion in this field. She also touches upon the possible changes in the competition between managers brought about by the Patient Capital Review.